A study assessed the impact of RYGB on the metabolic response to orally administered glucose, specifically examining levels of glucose, insulin, VIP, neurotensin, and motilin in eight morbidly individuals with obesity, both pre- and postoperatively [66]. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.